RxDoctor Payments Data

Robert Bass, MD

Hand Surgery · Dallas, TXNPI 1558370924

Payments from drug & device makers

$777in general payments, 2019–2025

Across 23 payments — averaging $33.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$257
  • Stryker$223
  • Exsomed Corporation$65
  • Johnson & Johnson$59
  • Smith+Nephew$54
  • Amgen$37
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Endo Pharmaceuticals Inc.7$257
Stryker3$223
Exsomed Corporation1$65
Johnson & Johnson(2 entities)3$59
Smith+Nephew3$54
Amgen2$37
ERMI LLC1$32
Orthofix Medical, Inc.1$22
Ferring Pharmaceuticals Inc.1$14
Sanofi-aventis U.S. LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$777 in reported general payments places this provider in the 25th percentile of 170 hand surgery providers in Texas.

See all hand surgery providers in Texas

Medicare billing

Part B allowed, 2024
$25,322
Medicare patients
60
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam15$28

Paid to pharmacies, not to this prescriber.

Other hand surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →